Q-omics provides the consensus-scored SPG21 profile across patient tissues and cancer cell-line models. SPG21 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPG21 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SPG21 RNA expression shows 18,925 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where SPG21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPG21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPG21 survival associations across molecular data types. SPG21 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPG21 RNA expression–survival associations across cancer types. High SPG21 expression shows unfavorable associations in ACC, MESO, LAML, HNSC, KICH and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPG21 RNA expression.
This table summarizes SPG21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SPG21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPG21 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, COAD, LIHC and STAD. The HNSC box plot shows higher SPG21 RNA expression in tumor versus normal tissue (log2 FC = +1.038, t-test p < 0.001).
This table shows molecular features associated with SPG21 in patient tissues and cancer cell lines. In patient samples, SPG21 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPG21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
